Drug Trial Radar · NCT06363851
Single-ascending Dose Study of Kylo-11 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
May 16, 2024
Primary completion
Jun 17, 2025
Study completion Dec 7, 2025
Sponsor
- Lead sponsor
- Kylonova (Xiamen) Biopharma co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Apr 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy volunteers. Approximately 60 subjects with baseline Lp(a) levels of 75-200 nmol/L are enrolled in the SAD part including dose levels of 9 mg, 30 mg, 75 mg, 225 mg, 450 mg, and 600 mg (Cohort 1-6) to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Kylo-11. Additionally, the dose of 225 mg is further evaluated in healthy participants with baseline Lp(a) level\>200 nmol/L (Cohort 7).
Conditions
- Cardiovascular Diseases
Interventions
Kylo-11Drug
Administered SC.
PlaceboDrug
Administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: up to Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chengdu Xinhua Hospital
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.